Why Epiminder (ASX:EPI) can now offer its epilepsy implant to teenagers after FDA clearance

Sonal Goyal

04 November 2026 09:58 PM AEDT

Why Epiminder (ASX:EPI) can now offer its epilepsy implant to teenagers after FDA clearance

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Key Highlights

• The FDA cleared the Minder System for patients aged 12 and older.

• The clearance widens the potential patient pool.

• Study progress and spending remain key items to watch.

• The company is a medical device Business classed in Health Care Equipment.

Epiminder (ASX:EPI) has widened the potential patient pool for its implanted epilepsy monitor after the US Food and Drug Administration cleared the Minder System for patients aged 12 and older on 30 October 2026. The device was previously cleared only for adults aged 18 and over, so the decision opens a new age group to a product that has yet to earn revenue.

What the Minder System does

Epiminder (ASX:EPI) is a medical device company, classified by the ASX as Health Care Equipment and Services. Its Minder System is a minimally invasive implantable continuous EEG monitor for people with drug-resistant epilepsy.

It has three parts: an electrode array placed under the scalp, a telemetry unit behind the ear, and a wearable that charges the device and sends data to a secure cloud platform for remote review. The company says Placement does not penetrate the skull.

Why the clearance matters

The company says continuous ambulatory monitoring of adolescents in the US typically meant a stay in a hospital epilepsy monitoring unit. Minder allows monitoring at home and school, which is the commercial logic behind the label expansion.

Epiminder (ASX:EPI) cited an estimated 3.4 million Americans with epilepsy, about a third of whom have drug-resistant disease. These are company figures from its release. The ASX announcement carries a headline age range of 12 to 75, but the body text sets no upper limit, so the precise label should be checked against the FDA record.

Study progress and spending

The company's 100th patient was enrolled in its US DETECT study in mid-October 2026. The target is up to 210 participants, with enrolment due to finish by the end of the first half of calendar 2027. The company expects 125 patients by December 2026, and 23 US sites are active out of up to 25 planned.

For the September 2026 quarter, Epiminder (ASX:EPI) reported cash of A$65.1 million, no borrowings, down from A$75.8 million at 30 June 2026, and a net operating cash outflow of A$10.5 million. It spent A$5.7 million on Research and Development in the quarter.

Full-year FY27 cash outflow guidance is A$45 million to A$48 million, which the company says funds operations well into calendar 2028. That guidance excludes any research and development tax incentive.

The financial picture

The year to 30 June 2026 produced no revenue. Epiminder (ASX:EPI) reported other income and interest of A$2.1 million and a loss of A$42.7 million, compared with a loss of A$31.8 million in FY25.

The company listed on the ASX on 1 December 2025 after raising A$125 million through 83.3 million shares at A$1.50. It ended June 2026 with A$75.8 million in cash and term deposits and no debt.

Its next-generation device is being developed with Cochlear, which is both the Manufacturing partner and the largest single shareholder, according to the annual report. The company is targeting FDA clearance for that device in the second half of calendar 2027 and a broader US launch in the first half of 2028.

Risks and dates ahead

Epiminder (ASX:EPI) lists reimbursement, the success of the DETECT study, reliance on third parties, product and regulatory failure, and cyber security among its key risks. A US hospital payment of US$27,700 applied in 2026, with a preliminary CY2027 figure of US$31,600 and a final rule expected in November 2026. That payment code covers sub-scalp implantation procedures.

Management is also changing. Chief financial officer Mark McLellan announced on 4 November 2026 that he will leave on 26 February 2027, and a search for a replacement is under way. The Annual General Meeting was held on 30 October 2026, alongside an operating update.

A label expansion does not create sales on its own, and Revenue still depends on reimbursement, clinician adoption and the next-generation device reaching market.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.